Protocol Title : A Randomised, open labelled study in anti ... - EME

More documents

Recommendations

Info

Protocol Version 3 14/01/2013 participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study The PI reserves the right to exclude patients at his centre if they have concerns regarding compliance with the study procedures or any other aspect of the study eligibility not necessarily limited to the above exclusion criteria. 3.4 Criteria for Premature Withdrawal 3.4.1 Subject Withdrawal Criteria A subject may withdraw from the study at any time at his/her own request, or may be withdrawn at any time at the discretion of the investigator for safety, behavioral or administrative reasons. 3.4.2 Subject Withdrawal Procedures If subjects prematurely discontinue the study, additional subjects may be enrolled as replacement subjects and assigned to the same treatment sequence at the discretion of the Sponsor. A final visit assessment will be made if the patient agrees. 4 INVESTIGATIONAL MEDICINAL PRODUCT 4.1 List and definition of each IMPs Rituximab Rituximab is a genetically engineered chimeric mouse/human monoclonal antibody representing a glycosylated immunoglobulin with human IgG1 constant regions and murine light-chain and heavychain variable region sequences. Tocilizumab Tocilizumab humanised IgG1 monoclonal antibody against the human interleukin-6 (IL-6) receptor produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology 4.2 Formulation of IMP Rituximab Rituximab is available as 50ml single-use vials containing 500mg rituximab for infusion (10mg/ml) Rituximab is a clear, colourless liquid Tocilizumab Tocilizumab is available in 20mg/ml vials in a concentrate for intravenous infusion. The vials are available in 4ml (80mg), 10ml (200mg), and 20ml (400mg). 4.3 IMP Supply Rituximab Rituximab will be prescribed according to NICE guidelines and thus will be sourced from the NHS supply at each site. Tocilizumab Tocilizumab will be prescribed a according to NICE guidelines and thus will be sourced from the NHS supply at each site. 4.4 Prescription of IMP Rituximab Rituximab will be prescribed by a physician as a member of the study team, using standardised prescription forms. A copy of all prescription forms will be provided to the monitor. Study: R4RA EudraCT: 2012-002535-28 18 / 34
Protocol Version 3 14/01/2013 Tocilizumab Tocilizumab will be prescribed by a physician as a member of the study team, using standardised prescription forms. A copy of all prescription forms will be provided to the monitor. 4.5 Preparation and Administration of IMP 4.5.1 Rituximab Preparation will be performed by a suitably trained member of the study team as per local policy Instructions for Dilution and Suitable Diluent: • Aseptically withdraw 1000mg (100ml) of rituximab. • Slowly add the total volume of rituximab (100mls) to a 500ml bag of sodium chloride 0.9%. To mix, gently invert the bag in order to avoid foaming. Do not shake. • The final concentration of the drug should be between 1-4mg/ml (in this case it will be 1.67mg/ml). • Care must be taken to ensure the sterility of the prepared solution – aseptic technique must be observed. • Inspect the bag visually for any particulate matter and discolouration prior to administration – discard the solution if observed. • The prepared infusion should be used immediately. Method and Rate of Administration: Pre-medication should be prescribed and administered 30 minutes prior to the start of infusion: Drug Dose Route Frequency Methylprednisolone 100mg IVI Stat Chlorphenamine 10mg IVB Stat Paracetamol 1000mg PO Stat Observations e.g. temperature, blood pressure, pulse and respiratory rate should also be carried out prior to the start of infusion. Using IV Volumat Pump The Rituximab entry in the pump library defaults to 1000mg in 600ml (as described above) and defaults to an initial rate of 50mg/hr (30mls/hour). First infusion of each course IV infusion: Initial rate: 50 mg/hr (30mls/hour); increase rate by 50 mg/hr (30mls/hour) every 30 minutes if tolerated, to a maximum of 400 mg/hr (240mls/hour). Rate – mg/hour Rate – mls/hour Initial rate 50mg/hour 30mls/hour After 30mins (if tolerated) 100mg/hour 60mls/hour After 30mins (if tolerated) 150mg/hour 90mls/hour After 30mins (if tolerated) 200mg/hour 120mls/hour After 30mins (if tolerated) 250mg/hour 150mls/hour Study: R4RA EudraCT: 2012-002535-28 19 / 34
Page 1 and 2:
Protocol Title : A Randomised, open
Page 3 and 4: Chief Investigator Agreement Page T
Page 5 and 6: Contact details: CPTU Contact: Beno
Page 7 and 8: Statistical Methodology and Analysi
Page 9 and 10: Contents ! 1. INTRODUCTION 11 1.1.
Page 11 and 12: 1 INTRODUCTION ! 1.1 Background Rhe
Page 13 and 14: 1.3 Clinical Data 1.3.1 Rituximab C
Page 15 and 16: ! response is associated with absen
Page 17 and 18: ! 3 STUDY POPULATION 3.1 Number of
Page 19 and 20: ! • Slowly add the total volume o
Page 21 and 22: 4.4 IMP Stability Rituximab RIituxi
Page 23 and 24: ! A baseline synovial biopsy is man
Page 25 and 26: ! Small response - CDAI50 ≥ 50% i
Page 27 and 28: ! (the former usually precedes the
Page 29 and 30: ! 6.3 Investigators Assessment 6.3.
Page 31 and 32: ! 7.2 Secondary Endpoint Efficacy A
Page 33 and 34: ! completed screening procedures an
Page 35 and 36: 9 TRIAL COMMITTEES ! 9.1 Trial Mana
Page 37 and 38: Protocol Version 3 14/01/2013 Proto
Page 39 and 40: Protocol Version 3 14/01/2013 Chief
Page 41 and 42: Protocol Version 3 14/01/2013 Conta
Page 43 and 44: Protocol Version 3 14/01/2013 Stati
Page 45 and 46: Protocol Version 3 14/01/2013 Conte
Page 47 and 48: Protocol Version 3 14/01/2013 1 INT
Page 49 and 50: Protocol Version 3 14/01/2013 1.3 C
Page 51 and 52: Protocol Version 3 14/01/2013 medic
Page 53: Protocol Version 3 14/01/2013 3 STU
Page 57 and 58: Protocol Version 3 14/01/2013 Log)
Page 59 and 60: Protocol Version 3 14/01/2013 a - I
Page 61 and 62: Protocol Version 3 14/01/2013 • F
Page 63 and 64: Protocol Version 3 14/01/2013 • S
Page 65 and 66: Protocol Version 3 14/01/2013 optim
Page 67 and 68: Protocol Version 3 14/01/2013 days
Page 69 and 70: Protocol Version 3 14/01/2013 negat
Page 71 and 72: Protocol Version 3 14/01/2013 The s
Page 73 and 74: Protocol Version 3 14/01/2013 (and
show all

Protocol Title : A Randomised, open labelled study in anti ... - EME

Create successful ePaper yourself

Delete template?

Save as template?